Celecoxib exposures reported to Texas poison control centers from 1999 to 2004.
Concerns have been raised about the safety of celecoxib. This study described the pattern of exposures involving only celecoxib (isolated exposures) reported to Texas poison control centers from 1999 to 2004. The mean dose was 701 mg. The patient age distribution was < or = 5 years (48%), 6-19 years (8%), and > or = 20 years (44%). In 78% of cases, exposure was unintentional. Of the exposures, 74% were managed outside of health care facilities. The final medical outcome was classified as no effect for 82% of the cases, and minor effects for 12% of the cases. Adverse clinical effects were listed for 5% of the patients, the most frequently reported being rash (3%), drowsiness (3%), pruritus (2%), and vomiting (2%). The most frequently listed treatment was decontamination by dilution (43%) or food (32%). The majority of isolated celecoxib exposures could be managed outside of health care facilities, and the outcome was generally favorable.
Forrester
M B
MB
Epidemiology and Surveillance Unit, Texas Department of State Health Services, 1100 W 49th Street, Austin, TX 78756, USA. mathias.forrester@dshs.state.tx.us
D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000506:poisoning*; D000068579:Celecoxib; D002648:Child; D002675:Child, Preschool; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000506:poisoning*; D005260:Female; D006801:Humans; D008297:Male; D011039:Poison Control Centers / Q000706:statistics & numerical data; D011041:Poisoning / Q000453:epidemiology; D011720:Pyrazoles / Q000009:adverse effects* / Q000506:poisoning*; D013449:Sulfonamides / Q000009:adverse effects* / Q000506:poisoning*; D013781:Texas / Q000453:epidemiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib